Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5887773 | Seminars in Arthritis and Rheumatism | 2014 | 16 Pages |
Abstract
Current evidence on the use of biological therapies for SV is mainly based on uncontrolled, observational data. Rituximab is not inferior to cyclophosphamide for remission induction in AAV and might be superior in relapsing disease. Infliximab and adalimumab are effective as steroid-sparing agents. Etanercept is not effective to maintain remission in patients with granulomatosis with polyangiitis, and serious adverse events have been reported. For LVV, both infliximab and etanercept had a role as steroid-sparing agents, and tocilizumab might be effective also for remission induction in LVV.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
LucÃa MD, MSc, EstÃbaliz MD, VÃctor M. MD, PhD, Ricardo MD, PhD, Íñigo MD, José MarÃa MD, PhD, Santiago MD, PhD,